Chad Patterson is Executive Vice President of Global Marketing at Dexcom.
In this role, Chad is responsible for global product management, design, clinical education, customer experience, research, public relations, and healthcare provider and direct-to-consumer marketing.
Since joining Dexcom in 2015, Chad has had multiple, successive positions of increased responsibility, including Senior Vice President, Global Marketing and Product Marketing. He established the direct-to-consumer and public relations functions for Dexcom and proceeded to build them into leaders in the industry.
Prior to Dexcom, Chad led marketing efforts for Nestlé both in Switzerland and the US on iconic brands such as Coffee-Mate, NESCAFÉ, Nesquik, Ovaltine, Cocoa, Carnation, Jamba Energy Drinks, and Hot Pockets.
Chad earned a Bachelor of Arts from Gonzaga University, where he played Division I soccer, and a Master of Business Administration from University of Southern California, Marshall School of Business.
What is Chad Patterson's net worth?
The estimated net worth of Chad Patterson is at least $2.73 million as of August 2nd, 2024. Mr. Patterson owns 37,133 shares of DexCom stock worth more than $2,729,276 as of November 14th. This net worth approximation does not reflect any other assets that Mr. Patterson may own. Learn More about Chad Patterson's net worth.
How do I contact Chad Patterson?
Has Chad Patterson been buying or selling shares of DexCom?
Chad Patterson has not been actively trading shares of DexCom during the last quarter. Most recently, Chad Patterson sold 777 shares of the business's stock in a transaction on Monday, May 9th. The shares were sold at an average price of $342.77, for a transaction totalling $266,332.29. Following the completion of the sale, the executive vice president now directly owns 13,675 shares of the company's stock, valued at $4,687,379.75. Learn More on Chad Patterson's trading history.
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 9/9/2024.
